Related Experiment Video
Updated: May 7, 2025
07:44
A Porcine Model of Acute Autologous Pulmonary Embolism
Published on: September 6, 2024
246
Management of Pulmonary Embolism: A Single-Center Experience
1From the University of Kentucky College of Medicine, Lexington.
Southern Medical Journal
|January 3, 2025
Summary
Pulmonary embolism (PE) management varies by risk. Low- and intermediate-risk patients typically receive anticoagulation, while high-risk patients may need advanced therapies for better outcomes.
Area of Science:
- Cardiology
- Pulmonary Medicine
- Vascular Medicine
Background:
- Pulmonary embolism (PE) is a significant cause of cardiovascular mortality.
- Effective management strategies are crucial for improving patient outcomes.
- Understanding current treatment patterns is essential for quality improvement initiatives.
Purpose of the Study:
- To evaluate the current clinical management of acute pulmonary embolism.
- To assess adherence to risk stratification guidelines in PE treatment.
- To analyze outcomes based on PE risk stratification at an academic institution.
Main Methods:
- Retrospective chart review of 775 patients with acute PE from January 2016 to June 2019.
- Utilized American Heart Association guidelines for PE risk stratification.
- Analyzed anticoagulation strategies, advanced therapies, and in-hospital mortality.
Main Results:
- Low-risk PE patients (n=409) were primarily treated with heparin/enoxaparin (92%), with a 0.5% mortality rate.
- Intermediate-risk PE patients (n=322) predominantly received anticoagulation (99.4%), with a 2.5% mortality rate.
- High-risk PE patients (n=66) had a 39% mortality rate and frequently required advanced therapies (71%).
Conclusions:
- Proper risk stratification is paramount in managing pulmonary embolism.
- Anticoagulation is effective for low- and intermediate-risk PE patients.
- High-risk PE patients with RV strain and hemodynamic instability benefit from advanced therapies.
Related Concept Videos
01:26Flail Chest-II
132
Managing flail chest, a condition characterized by a segment of the chest wall moving independently from the rest of the thoracic cage, requires a comprehensive approach. It includes a thorough assessment of the patient's condition, a diagnostic evaluation to determine the extent of the injury, and the implementation of appropriate medical interventions tailored to the individual's needs.
Assessment:
1. Clinical Evaluation:
History:
Assessment:
1. Clinical Evaluation:
History:
132
01:27Pneumothorax-II
104
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
104
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
97
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
97